Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1359-1362

  Carles, J ^a,h   Esteban, E ^b   Climent, M ^c   Font, A ^d   Gonzalez Larriba, J L ^e   Berrocal, A ^f   Garcia Ribas, I ^g   Marfa, X ^h   Fabregat, X ^a   Albanell, J ^a   Bellmunt, J ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g ELI LILLY AND COMPANY   (Spain)

^h Centro de Investigation Basica Sanofi Aventis   (Spain)

Author keywords

Bladder cancer; Gemcitabine; Oxaliplatin; Unfit patients

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY PELVIS CANCER; LIVER TOXICITY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; URETER CANCER; UROGENITAL TRACT CANCER; VISCERAL METASTASIS;

EID: 34548181558     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm160     Document Type: Article

References (18)

1. Stemberg CN, Yagoda A, Scher HI et al. Mathotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
2. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
3. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-1212.
4. Moore MJ, Tannock IF, Ernst KS et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 12: 3441-3445.
5. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 17: 3068-3077.
6. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52(12): 1855-1865.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31-41.
8. Therasse P, Arbuck SG, Elsenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
9. Mavroudis D, Kourousis C, Kakolyris S et al. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report. Semin Oncol 2000; 27 (1 Suppl 2): 25-30.
10. Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy. Cancer 2003; 97(9): 2180-2186.
11. Linardou H, Aravantinos G, Efstathiou e et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004; 64(3): 479-484.
12. Carles J, Nogué M, Domenech M et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59(1): 24-27.
13. Theodore C, Bidault F, Bouvet-Forteau N et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 2006; 17: 990-994.
14. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17(10): 3173-3181.
15. Bellmunt J, Guillen V, Paz-Ares L et al. Gemcitabine/paclitaxel based three durgs regiments in advanced urothelial cancer. Eur J Cancer 2000; Suppl 2: 17-25.
16. Small EJ, Lew D, Redman BG et al. Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point. J Clin Oncol 2000; 13: 2537-2544.
17. Meluch A, Greco A, Burris H et al. Gemcitabine and paclitaxel in combination for advanced transitional cell carcinoma of the urothelial tract: A trial of the Minnie Pearl Research Network. J Clin Oncol 2001; 19: 3018-3024.
18. Stemberg C, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 15(92): 2993-2998.